MACAU DAILY TIMES 澳門每日時報

Top Menu

  • Our Team
  • Editorial Statute
    • Code of Ethics
    • Privacy Policy
    • Terms and Conditions
  • Archive
    • PDF Editions
  • Contacts
  • Extra Times
    • Drive In
    • Book It
    • tTunes
    • Features
    • World of Bacchus
    • Taste of Edesia

Main Menu

  • Home
  • Macau
    • Photo Shop
    • Advertorial
  • Interview
  • Greater Bay
  • Business
    • Corporate Bits
  • China
  • Asia
  • World
  • Sports
  • Opinion
    • Editorial
    • Our Desk
    • Business Views
    • China Daily
    • Multipolar World
    • The Conversation
    • World Views
  • Our Team
  • Editorial Statute
    • Code of Ethics
    • Privacy Policy
    • Terms and Conditions
  • Archive
    • PDF Editions
  • Contacts
  • Extra Times
    • Drive In
    • Book It
    • tTunes
    • Features
    • World of Bacchus
    • Taste of Edesia
logo
FOUNDER & PUBLISHER Kowie Geldenhuys
EDITOR-IN-CHIEF Paulo Coutinho
Macau,

MACAU DAILY TIMES 澳門每日時報

  • Home
  • Macau
    • Photo Shop
    • Advertorial
  • Interview
  • Greater Bay
  • Business
    • Corporate Bits
  • China
  • Asia
  • World
  • Sports
  • Opinion
    • Editorial
    • Our Desk
    • Business Views
    • China Daily
    • Multipolar World
    • The Conversation
    • World Views
  • China-Russia-US Heads of State Declaration toward Peace

  • APEC leaders back Shenzhen trade agenda as Xi meets Trump and Putin

  • Lawmakers call for stronger building management and measures to stabilize property market

  • Bill sets five grounds for dissolution of civil associations

  • Pansy Ho urges unified Greater Bay Area tourism strategy

  • Lawmakers get more speaking time under revised policy debate format

Macau
Home›Macau›Patients struggle to get new Hepatitis C treatment in Macau

Patients struggle to get new Hepatitis C treatment in Macau

By Catarina Pinto
Monday, May 25, 2015
164
0
 A course of a 12-week treatment with Sofosbuvir in some European countries can cost MOP360,000

A course of a 12-week treatment with Sofosbuvir in some European countries can cost MOP360,000

Learning that a silent killer has slowly taken control of your body is one shocking revelation. But Hepatitis C patients have recently received life-changing news: a new effective – yet costly – drug can cure most cases of Hepatitis C in 12 weeks with few side effects. However, patients are struggling to get the new treatment in Macau, although the Health Bureau (SSM) has assured sufferers that the new drug has been listed and will be administered in accordance with a medical assessment process.
A Macau resident, who wishes to remain anonymous, told the Times that she has been waiting for treatment with Sovaldi (Sofosbuvir) for over a year. Radio Macau in March reported a similar case of another patient who’s been waiting and hoping for a treatment while suffering from other illnesses at the same time.
According to the World Health Organization (WHO), treatment with Sofosbuvir, which was made available in 2013, is recommended in genotypes 1,2,3 and 4 HCV infection, given in a combination with other drugs. It is particularly recommended to those who cannot access other treatments in the market after developing cirrhosis, one of Hepatitis C’s most commonly related diseases.
Last year, having sought treatment for other health problems and after running multiple blood tests, the Macau resident was informed that she had a number of other diseases, including diabetes, cirrhosis, portal hypertension, esophageal varices and Hepatitis C.
Although acknowledging that the local public hospital doctors were very helpful in dealing with her case, she said that when it comes to portal hypertension and esophageal varices related risks, she was not given comprehensive information.
While spending some time back in her home country, she was forced to seek urgent medical treatment there, which involved several blood transfusion procedures.
Having later learned that the new Hepatitis C drug was already available in Macau, she returned to the city, where she has been living and working for the past 30 years, resorting once again to Macau’s public hospital.
“The only thing I want is to be treated (…) Doctors said the new drug was already here. So I decided to come back and seek treatment here. So when I booked an appointment I really thought I would be getting treated soon. However, I was told that I would have to wait due to bureaucracy. I am still waiting. Bureaucracy has been their only excuse,” the resident revealed.
The Times contacted the Health Bureau seeking comments on Sofosbuvir’s availability in Macau, its price, how many patients are or will be subjected to treatment with the new drug, and the criteria outlined to prescribe Sofosbuvir to Macau patients.
Despite confirming that the medication is available in the territory, SSM acknowledged that Sofosbuvir has not yet been used to treat any patient in Macau.
p5-renato-marques-6I0A9977“The Conde de São Januário Hospital offers treatment for Hepatitis C in accordance with internationally recognized and effective course of treatments and drugs. The new drug against Hepatitis C – ‘Sofosbuvir’ – has already been listed in Macau and we’re planning its use in patients for whom the traditional course of treatment is inefficient or patients whose bodies cannot tolerate the usual drugs,” SSM said, adding that patients will be subject to “observations on the efficiency of this treatment.”
The bureau further stressed that, “the hospital will plan a course of treatment addressing each patient in accordance with their actual condition.”
Furthermore, it said that Sofosbuvir will be administered to sufferers in need of this particular drug, following an assessment by a medical team.
“So far the new drug has not been used to treat any patient [here],” it reiterated.
The Health Bureau did not reply to some of The Times’ questions, namely on how much the course of treatment will cost; and what criteria will be considered when deciding whether to prescribe Sofosbuvir or not.
A 12-week treatment course with Sofosbuvir in some European countries can cost up to EUR41,000 (MOP360,000).
The Macau resident told the Times that the former treatment does not apply to her, because she has developed cirrhosis. Moreover, the traditional course of treatment is believed to be far more invasive, as also acknowledged by the WHO and doctors worldwide.
“The former treatment involved taking pills and injections. It took longer for patients to be treated and the treatment was very invasive. The new drug is believed to be much less invasive,” the Macau resident told The Times.
Although SSM reiterated that the new drug has been listed in Macau, the patient interviewed by the Times was told that bureaucracy issues were actually hampering its immediate use.
“The problem here is bureaucracy, because there must be a public tender to produce and distribute this drug. [The new drug] is very costly. I fear that I could die from one of my liver-­related diseases but, in reality, it’s because I was not treated for Hepatitis C. And they will never admit it,” the resident said.
“There have to be exceptions to bureaucracy. Otherwise people die. They do not see this as something serious, because it does not have the same dimension of a flu that can be easily spread. But you know… bureaucracy kills too.”
The Macau resident added that she has always been treated well at the pubic hospital, and this is the first time she has had reason to raise criticism.
The Times attempted to interview an infectious disease specialist working for the public hospital, but the doctor was not authorized to share any insights on Hepatitis C.

Gilead patents challenged

A U.S. group is seeking to void patents in five countries for Gilead Sciences Inc’s expensive Hepatitis C drug Sovaldi (Sofosbuvir), in an attempt to provide nearly 60 million Hepatitis C patients with access to a cheaper generic version, Reuters reported last week. Strongly recommended by the World Health Organization (WHO), the new drug can cost up to USD84,000 for a single course of treatment in the United States, according to a New York Times report last week. The Initiative for Medicines, Access and Knowledge, a New York-based legal group, has filed challenges in Argentina, Brazil, China, Russia and Ukraine.

Hepatitis in Macau

Hepatitis C is an illness that must be reported to Macau health authorities. According to figures released by the Health Bureau, 100 Hepatitis C patients last year were followed by infectious disease specialists at the public hospital.
In a statement issued last March, the Health Bureau revealed that the number of acute Hepatitis C cases recorded a decrease over the past 12 years.
2002 saw the highest surge in the number of cases, with 135 people infected. The Health Bureau added that in 2013, three cases were confirmed. In 2011, 2012 and 2014, no cases were recorded.
The issue with Hepatitis C though is that many cases are believed to remain undiagnosed, as stated in a report published by The Guardian in February.
Dr Chloe Orkin, a British consultant and honorary reader in HIV medicine at Barts Health NHS Trust, told the Guardian that about half of the 200,000 people in the UK believed to have chronic hepatitis C are undiagnosed.
She recalled  one of the major problems being that the authorities do not know where these people are and in what populations.

Battling the silent killer

Hepatitis C has been dubbed the silent killer as “it can cause chronic liver disease that progresses insidiously, unnoticed for decades,” wrote Patrick Strudwick from the Guardian, in a report published this February.
According to a World Health Organization factsheet, Hepatitis C is a liver disease caused by the Hepatitis C virus, which can cause both acute and chronic hepatitis infection, ranging from a mild infection to a serious, lifelong disease.
A significant number of those infected chronically will develop liver cirrhosis or liver cancer. The WHO estimates that 130 to 150 million people worldwide have chronic hepatitis C infection.
Some patients and physicians have raised concerns over the misconception that Hepatitis C is mostly spread among people taking drugs and sharing needles.
The Macau resident interviewed by the Times recalled that Hepatitis C, unfortunately, can be spread via a different number of ways and further awareness about the illness is needed.
According to WHO, the most common modes of infection of this bloodborne virus are through unsafe injection practices, inadequate sterilization of medical equipment, and unscreened blood and blood products. There are also cases, although less common, in which the virus was transmitted sexually.
Hepatitis C is not spread through food or water, or by casual contact, such as kissing, hugging, or sharing food and drinks with an infected person. The virus, however, can survive outside the body for some days and for weeks within syringes.

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on WhatsApp (Opens in new window) WhatsApp
  • Print (Opens in new window) Print

Like this:

Like Loading…

Related

Previous Article

Former CEO’s lawsuit against Sands China stays ...

Next Article

Education | DSEJ intends to penalize parents ...

Related articles More from author

  • HeadlinesMacau

    Macau eyes night economy as visitor numbers rise, overnight lags

    Tuesday, October 6, 2026
    By Yuki Lei, MDT
  • HeadlinesMacau

    Toddler passes away from blast injuries; authorities investigate possible manslaughter

    Friday, March 14, 2025
    By -
  • AdvertorialCorporate BitsMacau

    Exclusive Japanese Gastronomic Extravaganza at MGM

    Thursday, March 7, 2024
    By MGM Macau PR
  • Macau

    Covid-19 Health authorities report another three imported asymptomatic cases

    Monday, February 21, 2022
    By -
  • MacauOnline

    Approved residential and commercial loans decrease

    Friday, February 11, 2022
    By -
  • Macau

    French Film Festival to run until May 18

    Friday, May 13, 2016
    By -

Leave a reply Cancel reply

You must be logged in to post a comment.

  • Drive In

    ‘X-Men: Apocalypse’ satisfies in superhero summer

  • HeadlinesMacau

    Hengqin Cargo Terminal to open doors by mid-2027

  • HeadlinesMacau

    Five Zone A public housing projects on hold

DAILY EDITION

Friday, November 20, 2026 – edition no. 5079
Friday, November 20, 2026 – edition no. 5079

Greater Bay

MDT MACAU GRAND PRIX SPECIAL

November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
« Oct    

Timeline

  • Friday, November 20, 2026

    China-Russia-US Heads of State Declaration toward Peace

  • Friday, November 20, 2026

    APEC leaders back Shenzhen trade agenda as Xi meets Trump and Putin

  • Friday, November 20, 2026

    Lawmakers call for stronger building management and measures to stabilize property market

  • Friday, November 20, 2026

    Bill sets five grounds for dissolution of civil associations

  • Friday, November 20, 2026

    Pansy Ho urges unified Greater Bay Area tourism strategy

  • Friday, November 20, 2026

    Lawmakers get more speaking time under revised policy debate format

  • Friday, November 20, 2026

    Over 85% of resident owners say Iao Hon redevelopment cannot wait

  • Friday, November 20, 2026

    Porsche leads surprise charge in opening GT World Cup sessions

  • Friday, November 20, 2026

    Rivera leads provisional FR World Cup qualifying after crash-hit session

  • Friday, November 20, 2026

    Red flags interrupt F4 practice as Killion tops timesheets

Extra Times

Drive InExtra Times

‘Madden’ biopic can’t find a playbook to stick with

Which play to run is a question that can bedevil any football coach, and it’s also what dooms David O. Russell’s fumbled biopic “Madden.” “Madden” may sport an all-star cast ...
  • Juksunchae: A Study in Precision and Contemporary Korean Cuisine

    By Irene Sam, MDT
    Friday, November 20, 2026
  • Reframing the “Hundreds of Flavors”: Chiang and Ho at Zi Yat Heen

    By -
    Friday, November 20, 2026
  • Three chefs. One horizon. Six Michelin stars

    By Irene Sam, MDT
    Friday, November 13, 2026
  • James Gray delivers a milestone crime drama in ‘Paper Tiger’

    By MDT/AP
    Friday, November 13, 2026
  • Recent

  • Popular

  • China-Russia-US Heads of State Declaration toward Peace

    By XINHUA
    Friday, November 20, 2026
  • APEC leaders back Shenzhen trade agenda as Xi meets Trump and Putin

    By Times Reporter
    Friday, November 20, 2026
  • Lawmakers call for stronger building management and measures to stabilize property market

    By Yuki Lei, MDT
    Friday, November 20, 2026
  • Bill sets five grounds for dissolution of civil associations

    By Yuki Lei, MDT
    Friday, November 20, 2026
  • Pansy Ho urges unified Greater Bay Area tourism strategy

    By Nadia Shaw, MDT
    Friday, November 20, 2026
  • Lawmakers get more speaking time under revised policy debate format

    By -
    Friday, November 20, 2026
  • Over 85% of resident owners say Iao Hon redevelopment cannot wait

    By Yuki Lei, MDT
    Friday, November 20, 2026
  • Canidrome may have its days numbered, decision in ‘one or two months’

    By Paulo Coutinho, MDT
    Thursday, May 26, 2016
  • Animal Welfare | Macau: Anima slams Canidrome management for avoiding debate

    By -
    Wednesday, May 4, 2016
  • Editorial | Canidoomed

    By Paulo Coutinho, MDT
    Wednesday, June 1, 2016
  • Animal Welfare | Canidrome presented with ultimatum: close or move

    By Daniel Beitler, MDT
    Friday, July 22, 2016
  • Australia regulator cracks down on alleged exportation of dogs to Macau

    By Paulo Coutinho, MDT
    Friday, June 10, 2016
  • Animal rights | Canidrome: Anima in fresh airline negotiations as Canidrome closure looks more likely

    By Daniel Beitler, MDT
    Friday, May 27, 2016
  • USE OF ENGLISH IN MACAU | A ‘de facto’ official language

    By Catarina Pinto
    Monday, July 6, 2015
  • Contact our Administrator
  • Contact our Editor-in-Chief
  • Contacts
  • Our Team
  • Privacy Policy
  • Terms and Conditions
  • Editorial Statute
  • Code of Ethics
COPYRIGHT © MACAU DAILY TIMES 2008-2026. ALL RIGHTS RESERVED
MACAU DAILY TIMES
  • Home
  • Macau
    • Photo Shop
    • Advertorial
  • Interview
  • Greater Bay
  • Business
    • Corporate Bits
  • China
  • Asia
  • World
  • Sports
  • Opinion
    • Editorial
    • Our Desk
    • Business Views
    • China Daily
    • Multipolar World
    • The Conversation
    • World Views
  • Our Team
  • Editorial Statute
    • Code of Ethics
    • Privacy Policy
    • Terms and Conditions
  • Archive
    • PDF Editions
  • Contacts
  • Extra Times
    • Drive In
    • Book It
    • tTunes
    • Features
    • World of Bacchus
    • Taste of Edesia
Loading Comments...

You must be logged in to post a comment.

%d